Clinical Report: Complement Inhibition Slows GA in Eyes With Wet AMD
Overview
Complement inhibition therapy significantly reduced geographic atrophy (GA) progression by nearly 50% in patients with neovascular age-related macular degeneration (nAMD). The therapy did not increase choroidal neovascularization (CNV) activity, indicating its safety and efficacy in this patient population.
Background
Geographic atrophy is a leading cause of vision loss in patients with wet AMD, and effective treatment options are critical for preserving vision. Recent advancements in complement inhibition therapies offer a promising approach to slow GA progression. Understanding the impact of these therapies on both GA and CNV activity is essential for optimizing treatment strategies in affected patients.
Data Highlights
| Measure | Pre-Treatment | Post-Treatment |
|---|---|---|
| GA Lesion Growth Rate | 1.5 mm²/year | 0.8 mm²/year |
Key Findings
- Complement inhibition therapy reduced GA lesion growth by nearly 50%.
- Average GA growth rate decreased from 1.5 mm²/year to 0.8 mm²/year after treatment.
- Only 4 out of 33 eyes showed new signs of CNV activity during the study.
- Visual acuity remained stable over the 1-year follow-up period.
- Patients experienced longer intervals between anti-VEGF injections after starting complement therapy.
Clinical Implications
Clinicians can consider initiating complement inhibition therapy in patients with existing wet AMD to effectively slow GA progression without exacerbating CNV activity. This approach may lead to improved management of treatment intervals and overall patient outcomes.
Conclusion
Complement inhibition presents a viable treatment option for patients with wet AMD, effectively slowing GA progression while maintaining stability in CNV activity and visual acuity.
References
- Josh O. Wallsh, MD, Retinal Physician, 2025 -- Complement Inhibition Slows GA in Eyes With Wet AMD
- Retinal Physician, 2025 -- Who Stops GA Therapy—and Why
- Retinal Physician, 2025 -- Complement Inhibition for Geographic Atrophy
- Retinal Physician, 2019 -- Complement Inhibitors for Treatment of Geographic Atrophy and Advanced Nonexudative AMD
- Oregon Health & Science University, 2025 -- Age-Related Macular Degeneration Preferred Practice Pattern®
- retinal physician — How I Work With My Patients on Complement Inhibitor Therapy for GA
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- Complement Inhibition Slows GA in Eyes With Wet AMD | Retinal Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.